Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5832.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,2941.0,1.0,=,2.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1816.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,575.0,1.0,=,3.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1087.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,229.0,1.0,=,4.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,874.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,239.0,1.0,=,3.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,843.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,261.0,1.0,=,3.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,650.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,190.0,1.0,=,3.4
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5658.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,2237.0,1.0,=,2.5
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,4310.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,1365.0,1.0,=,3.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,3383.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,282.0,1.0,=,12.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2292.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,756.0,1.0,=,3.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2247.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,725.0,1.0,=,3.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2071.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,647.0,1.0,=,3.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1973.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,928.0,1.0,=,2.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1865.0,1.0,Delta/K417N,19,T19R + T95I + G142D + E156G + Δ157-158 + W258L + K417N + L452R + T478K + K558N + P681R + D950N,1,=,547.0,1.0,=,3.4